Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Insight Molecular Diagnostics Inc. (IMDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
4Distinct source URLs
9High confidence
0.800Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Insight Molecular Diagnostics Inc. Suppliers
Ticker
Name
Confidence
Evidence
BIO-RAD
BIO-RAD
92%
The Company has a concentration in the volume of business transacted with Bio-Rad, its global strategic partner.
ission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, or reduce our ability t…
Reciprocal relationship from LCTX graph: Reciprocal relationship from IMDX graph: ission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercializ…
On February 20, 2026, iMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics for certain specimen collection-related services related to the Company’s GraftAss…
Reciprocal relationship from DGX graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from DGX graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from DGX grap…
CAREDX-INC-NATERA-INC
CAREDX-INC-NATERA-INC
85%
izations that conduct research in our field. Our competition will be determined in part by the potential indications for which our lead test candidates are developed and ultimately marketed. Addition…
CAREDX-INC-NATERA-INC-TRANSPLANT-GENOMICS-OMIXON
CAREDX-INC-NATERA-INC-TRANSPLANT-GENOMICS-OMIXON
85%
izations that conduct research in our field. Our competition will be determined in part by the potential indications for which our lead test candidates are developed and ultimately marketed. Addition…
Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: Reciprocal relationship from BIO graph: Reciprocal relationship from IMDX graph: s to raise capital to finance its ope…
s to raise capital to finance its operations. Item 1. Business. Overview We are a pioneering diagnostics technology company. Our mission is to democratize access to novel molecular diagnostic testing…
CALIFORNIA-NORIDIAN-HEALTHCARE-SOLUTIONS-LLC
CALIFORNIA-NORIDIAN-HEALTHCARE-SOLUTIONS-LLC
62%
to commercialize our products is dependent on availability and sufficiency of third-party payer coverage and our ability to ensure our tests remain reimbursed or attain reimbursement by Medicare, and…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
aterials may fluctuate based on a number of factors beyond our control, including changes in supply and demand, general economic conditions, labor costs, fuel related delivery costs, competition, imp…
CUSHING-VENTURES-LLC
CUSHING-VENTURES-LLC
62%
Company recorded impairments of $ 2.9 million and $ 11.7 million related to DetermaIO and DetermaCNI, respectively, as of December 31, 2025 . The significant unobservable inputs used related to Deter…
Insight Molecular Diagnostics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMDX-DEBT-10235
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
IMDX-DEBT
Debt stack $1.9M
90%
Market cache reports total debt of $1.9M.
IMDX-DEBT-10234
Warrants outstanding: 819767
90%
xbrl warrant detail from xbrl 2023-09-30.
Insight Molecular Diagnostics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Insight Molecular Diagnostics Inc..
Insight Molecular Diagnostics Inc. Ownership
Holder
Name
Confidence
Evidence
IMDX-OWNER-BROADWOOD-CAPITAL-INC
BROADWOOD CAPITAL INC
90%
13F overlay lists BROADWOOD CAPITAL INC as top holder; 43 tracked holders.
Insight Molecular Diagnostics Inc. Extended Supply Chain Network
